We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Scheduling amendments referred to expert advisory committee
Subdivision 3D.2 of the Therapeutic Goods Regulations 1990 (the Regulations) sets out the procedure to be followed where the Secretary receives an application under section 52EAA of the Therapeutic Goods Act 1989 (the Act) to amend the current Poisons Standard and decides to refer the proposed amendment to an expert advisory committee. These include, under regulation 42ZCZK, that the Secretary publish (in a manner the Secretary considers appropriate) the proposed amendment to be referred to an expert advisory committee, the committee to which the proposed amendment will be referred, and the date of the committee meeting. The Secretary must also invite public submissions to be made to the expert advisory committee by a date mentioned in the notice as the closing date, allowing at least 20 business days after publication of the notice. Such a notice relating to the final decisions herein was made available on the TGA website at Scheduling advisory committees: invitations for public comment on 31 August 2018 and closed on 28 September 2018. Public submissions received on or before this closing date were published on the TGA website at Public submissions on scheduling matters referred to the ACMS #25, ACCS #23 and Joint ACMS-ACCS #20 meetings held in November 2018, in accordance with regulation 42ZCZL.
Under regulation 42ZCZN of the Regulations, the Secretary, after considering the advice or recommendation of the expert advisory committee, must (subject to regulation 42ZCZO) make an interim decision in relation to the proposed amendment. If the interim decision is to amend the current Poisons Standard, the Secretary must, in doing so, take into account the matters mentioned in subsection 52E(1) of the Act (including, for example, the risks and benefits of the use of a substance, and the potential for abuse of a substance) and the scheduling guidelines as set out in the Scheduling Policy Framework for Medicines and Chemicals.
Under regulation 42ZCZP of the Regulations, the Secretary must, among other things, publish (in a manner the Secretary considers appropriate) the scheduling interim decision, the reasons for that decision and the proposed date of effect (for decisions to amend the current Poisons Standard, this will be the date when it is expected that the current Poisons Standard will be amended to give effect to the decision). Also in accordance with regulation 42ZCZP of the Regulations, the Secretary must invite the applicants and persons who made a submission in response to the original invitation under paragraph 42ZCZK(1)(d), to make further submissions to the Secretary in relation to the interim decisions by a date mentioned in the notice as the closing date, allowing at least 10 business days after publication of the notice. Such a notice relating to the interim decisions of substances initially referred to the November 2018 meetings of the Advisory Committee on Medicines Scheduling (ACMS #25), the Advisory Committee on Chemicals Scheduling (ACCS #23), and the Joint Advisory Committee on Medicines and Chemicals Scheduling (Joint ACMS-ACCS #20) was made available on the TGA website at Publication of interim decisions amending, or not amending, the current Poisons Standard, February 2019 on 7 February 2019 and closed on 7 March 2019. Public submissions received on or before this closing date will be published on the TGA website at Public submissions on scheduling matters in accordance with regulation 42ZCZQ.
Under regulation 42ZCZR of the Regulations, the Secretary may make a final decision by confirming, varying or setting aside the interim decision, but only after considering all relevant submissions and any advice received under request 42ZCZQ(2)(a). In accordance with 42ZCZS the Secretary publishes here the scheduling final decision, the reasons for that decision and the date of effect (for decisions to amend the current Poisons Standard, this will be the date when it is expected that the current Poisons Standard will be amended to give effect to the decision). These Secretary's final decisions and reasons related to:
- scheduling proposals initially referred to the November 2018 meeting of the Advisory Committee on Medicines Scheduling (ACMS #25);
- scheduling proposals initially referred to the November 2018 meeting of the Joint meeting of the Advisory Committees on Chemicals and Medicines Scheduling (ACCS-ACMS #20); and
- scheduling proposals initially referred to the November 2018 meeting of the Advisory Committee on Chemicals Scheduling (ACCS #23).
Scheduling amendments not referred to expert advisory committee
Subdivision 3D.3 of the Therapeutic Goods Regulations 1990 (the Regulations) sets out the procedure to be followed where the Secretary receives an application under section 52EAA of the Therapeutic Goods Act 1989 (the Act) to amend the current Poisons Standard and decides not to refer the proposed amendment to an expert advisory committee. These include, under regulation 42ZCZU, that the Secretary decides to make a final decision in relation to the proposed amendment without an interim decision. If the final decision is to amend the current Poisons Standard, the Secretary must, in doing so, take into account the matters mentioned in subsection 52E(1) of the Act (including, for example, the risks and benefits of the use of a substance, and the potential for abuse of a substance) and the scheduling guidelines as set out in the Scheduling Policy Framework for Medicines and Chemicals.
In accordance with 42ZCZX of the Regulations, the Secretary publishes here the scheduling final decision, the reasons for that decision and the date of effect (for decisions to amend the current Poisons Standard, this will be the date when it is expected that the current Poisons Standard will be amended to give effect to the decision). These Secretary's final decisions and reasons related to:
- New therapeutic Prescription Only medicines known as New Chemical Entities (NCEs).
Privacy and your personal information
The Therapeutic Goods Administration (TGA) will not publish information it considers confidential, including yours/other individuals' personal information (unless you/they have consented to publication) or commercially sensitive information. Also, the TGA will not publish information that could be considered advertising or marketing (e.g. logos or slogans associated with products), information about any alleged unlawful activity or that may be defamatory or offensive.
For general privacy information, go to Privacy. The TGA is part of the Department of Health and the link includes a link to the Department's privacy policy and contact information if you have a query or concerns about a privacy matter.
The TGA may receive submissions from the public on a proposed amendment to the Poisons Standard where there has been an invitation to the public for submissions on the proposal in accordance with the Therapeutic Goods Regulations 1990. These submissions may contain personal information of the individual making the submissions and others.
The TGA collects this information as part of its regulatory functions and may use the information to contact the individual who made the submissions if the TGA has any queries.
As set out above, the TGA is required to publish these submissions unless they contain confidential information.
If you request for your submission to be published in full, including your name and any other information about you, then the TGA will publish your personal information on its website. However, if at any point in time, you change your mind and wish for your personal information to be redacted then please contact the Scheduling Secretariat at medicines.scheduling@health.gov.au so that the public submissions can be updated accordingly.
Please note that the TGA cannot guarantee that updating the submissions on the TGA website will result in the removal of your personal information from the internet.
Please note that the TGA will not publish personal information about you/others without your/their consent unless authorised or required by law.
Enquiries
Any questions relating to submissions should be directed by email to medicines.scheduling@health.gov.au (for substances referred to the ACMS or Joint ACCS-ACMS) or chemicals.scheduling@health.gov.au (for substances referred to the ACCS).
Contents
- Part A - Final decisions on matters referred to an expert advisory committee (November 2018)
- 1. Advisory Committee on Medicines Scheduling (ACMS #25)
- 2. Joint meeting of the Advisory Committee on Chemicals and Medicines Scheduling (ACCS-ACMS #20)
- 3. Advisory Committee on Chemicals Scheduling (ACCS #23)
- Part B - Final decisions on matters not referred to an expert advisory committee
- 4. New Chemical Entities - medicines for human therapeutic use